GLP-1 시장 : 분자 유형별, 사용되는 활성화합물별, GLP-1 아고니스트 의약품 유형별, 아고니스트 유형별, 투여 경로별, 표적 적응증별, 주요 지역별 - 업계 동향과 세계 예측(-2035년)

GLP-1 Market by Type of Molecule, Active Compound Used, Type of GLP-1 Agonist Drugs, Type of Agonist Route of Administration, Target indication and Key Geographical Regions : Industry Trends and Global Forecasts, Till 2035

US $ 4,799 ￦ 6,868,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,999 ￦ 10,016,000

PDF (One-Location Site License)

PDF 보고서를 동일 사업장의 특정 사업 부문에 속한 모든 분들이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 10,599 ￦ 15,169,000

PDF (Department License)

PDF 보고서를 부서 단위로 12명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 17,999 ￦ 25,760,000

PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

세계의 GLP-1 시장 규모는 2035년까지의 예측 기간 중 11.1%의 CAGR로 확대하며, 현재 493억 달러에서 2035년까지 1,575억 달러로 성장할 것으로 예측됩니다.

세계보건기구(WHO)에 따르면 전 세계에서 10억 명 이상이 비만으로 고통받고 있으며, 그 중 6억 5,000만 명이 성인입니다. 비만으로 인해 연간 400만 명이 사망하는 것으로 추정됩니다. 또한 최근 연구에 따르면 전 세계에서 약 5억 3,000만 명의 성인이 당뇨병을 앓고 있으며, 그 중 98%는 2형 당뇨병으로 추정됩니다. 비만과 당뇨병의 부담 증가를 고려할 때, 안전하고 효과적인 의약품에 대한 요구가 증가하고 있습니다. 이에 따라 다양한 기업이 이러한 적응증을 타깃으로 한 후보 약물의 개발 및 평가에 착수하고 있습니다.

최근 GLP-1 약물이 유망한 대안으로 떠오르고 있으며, 15개의 GLP-1 약물이 다양한 적응증을 대상으로 상용화되고 있다는 점은 주목할 만합니다. 또한 현재 135개 이상의 신약 후보물질이 다양한 개발 단계에 걸쳐 평가되고 있습니다. 다양한 적응증에 대한 신약 승인과 각 회사의 광범위한 R&D 노력(GLP-1 약물전달 메커니즘 강화)에 힘입어 향후 10년간 GLP-1 치료제 시장은 꾸준한 성장을 보일 것으로 예상됩니다.

GLP-1 제제 후보의 약 60%는 현재 임상 개발 단계에 있으며, 대부분이 2형 당뇨병 및 비만 등의 대사성 질환을 대상으로 하고 있습니다. GLP-1 의약품의 현재 시장 구도는 신규 참여 기업과 기존 기업 양쪽 모두가 존재하는 단편적인 것이며, 이러한 기업의 대부분은 중국(36%)과 미국(28%)을 거점으로 하고 있습니다. GLP-1 의약품에 관한 최근 동향은 꾸준히 확대하고 있으며, 특히 이러한 거래의 약 50%가 의약품 개발과 상업화를 위해 패스닝된 것입니다. 라이프스타일의 변화, 소셜미디어의 영향, 유명인의 추천, 소비자에 대한 직접 광고가 GLP-1 의약품의 수요 급증으로 연결되고 있습니다. GLP-1 시장은 예측 기간 중 CAGR 11.1%로 성장할 것으로 예측되며, 2035년까지 생물제제 부문이 시장의 대부분의 점유율(65% 이상)을 차지할 것으로 예상됩니다.

세계의 GLP-1시장에 대해 조사했으며, 시장의 개요와 분자 유형별, 사용되는 활성화합물별, GLP-1 아고니스트 의약품 유형별, 아고니스트 유형별, 투여 경로별, 표적 적응증별, 주요 지역의 동향 및 시장에 참여하는 기업의 개요 등을 제공하고 있습니다.

목차

제1장 배경

제2장 조사 방법

제3장 경제 및 기타 프로젝트 특유의 고려 사항

제4장 개요

제5장 서론

제6장 시장 구도 : GLP-1 의약품

제7장 GLP-1 의약품 : 상세 기업 개요

제8장 GLP-1 의약품 : 기업 개요

제9장 파트너십과 협업

제10장 시장에 대한 영향 분석 : 촉진요인, 억제요인, 기회, 과제

제11장 세계의 GLP-1 시장

• 전제와 조사 방법
• 세계의 GLP-1 시장, 실적과 2035년까지 예측

제12장 GLP-1 시장, 분자 유형별

제13장 GLP-1 시장, 사용되는 활성화합물별

제14장 GLP-1 시장, GLP-1 아고니스트 의약품 유형별

제15장 GLP-1 시장, 아고니스트 유형별

제16장 GLP-1 시장, 투여 경로별

제17장 GLP-1 시장, 표적 적응증별

제18장 GLP-1 시장, 주요 지역별

제19장 GLP-1 시장, GLP-1 의약품 판매 예측

제20장 GLP-1 시장, 오테 의약품 개발 기업별

제21장 부록 1 : 표 형식 데이터

제22장 부록 2 : 기업·단체 리스트

KSA

영문 목차

영문목차

GLP-1 MARKET: OVERVIEW

As per Roots Analysis, the global GLP-1 market is estimated to grow from USD 49.3 billion in the current year to USD 157.5 billion by 2035, at a CAGR of 11.1% during the forecast period, till 2035.

The market sizing and opportunity analysis has been segmented across the following parameters:

Type of Molecule

• Biologics
• Small Molecules

Active Compound Used

• Dulaglutide
• Liraglutide
• Orforglipron
• Retatrutide
• Semaglutide
• Survodutide
• Tirzepatide
• Other Active Compounds

Type of GLP-1 Agonist Drugs

• Long-acting GLP-1 Agonist
• Short-acting GLP-1 Agonist

Type of Agonist

• Single agonist
• Dual agonist
• Tri-agonist

Route of Administration

• Oral
• Parenteral

Target Indication

• Alzheimer's Disease
• Non-Alcoholic Steatohepatitis
• Obesity
• Sleep Apnea
• Type 2 Diabetes

Key Geographical Regions

• North America (US, Canada)
• Europe (Germany, UK, France, Italy, Spain, Netherlands, Rest of Europe)
• Asia-Pacific
• Latin America

GLP-1 MARKET: GROWTH AND TRENDS

According to the World Health Organization (WHO), more than 1 billion individuals are suffering from obesity, worldwide; of these, 650 million individuals are adults. It is estimated that 4 million people die annually due to obesity. In addition, a recent study indicates that close to 530 million adult population suffers from diabetes globally; of these, 98% of the population is expected to have type 2 diabetes. Considering the growing burden of obesity and diabetes, there has been a rise in the need for safe and effective medications. As a result, various companies have started developing and evaluating potential candidates targeting these indications.

In the recent past, GLP-1 drugs have emerged as a promising option. It is worth highlighting that 15 GLP-1 drugs have been commercialized for targeting various indications. Additionally, more than 135 drug candidates are currently being evaluated across various phases of development. Driven by the new drug approvals (for different applications), and extensive R&D efforts of the companies (to enhance delivery mechanisms of GLP-1 drugs), the market is anticipated to witness steady growth in the coming decade.

GLP-1 MARKET: KEY INSIGHTS

The report delves into the current state of the GLP-1 market and identifies potential growth opportunities within the industry. Some key findings from the report include:

• More than 150 GLP-1 drug candidates, intended for the treatment of multiple indications, are currently either approved or being investigated by pharmaceutical companies.

• ~60% of the GLP-1 drug candidates are currently being evaluated in clinical stages of development; of these, most of the candidates target metabolic disorders, such as Type 2 diabetes and obesity.
• The current market landscape of GLP-1 drugs is fragmented, featuring the presence of both new entrants and established players; majority of these firms are based in China (36%) and the US (28%).
• Partnerships related to GLP-1 drugs have steadily grown in the recent past; notably, close to 50% of these deals were signed for drug development and commercialization.
• Lifestyle changes, influence of social media, celebrity endorsements and direct to consumer advertisements have led to a surge in the demand for GLP-1 drugs.
• The GLP-1 market is anticipated to grow at a CAGR of 11.1%, during the forecasted period; biologics segment is expected to capture the majority share (over 65%) of the market by 2035.

GLP-1 MARKET: KEY SEGMENTS

Currently, Small Molecules Occupy the Largest Share of the GLP-1 Market

Based on the type of molecule, the market is segmented into biologics and small molecules. At present, the small molecules segment holds the maximum share of the GLP-1 market. It is worth highlighting that owing to the unique physiological properties of biologics, including stability, specificity, selectivity and ability to block specific protein-protein interactions, the biologics segment is likely to grow at a relatively higher CAGR.

Survodutide Active Compound is the Fastest Growing Segment of the GLP-1 Market During the Forecast Period

Based on the active compound, the market is segmented into dulaglutide, liraglutide, orforglipron, retatrutide, semaglutide, survodutide, tirzepatide and other active compounds. At present, semaglutide holds the maximum share of the GLP-1 market. Further, it is worth highlighting that survodutide is likely to drive the market in the near future.

Currently, Long-Acting GLP-1 Agonists Occupy the Largest Share of the GLP-1 Market

Based on the type of GLP-1 agonists drugs, the market is segmented into short-acting GLP-1 agonist and long-acting GLP-1 agonist. At present, long-acting GLP-1 agonist holds the maximum share of the GLP-1 market and this trend is likely to remain the same in the forthcoming years. This can be attributed to the fact that the effect of the long-acting drug lasts longer than that of short-acting agonists. It is worth highlighting that short-acting GLP-1 agonist segment is likely to grow at a relatively higher CAGR.

At Present, Single-agonist Segment Occupies the Largest Share of the GLP-1 Market

Based on the type of GLP-1 agonist, the market is segmented into single-agonist, dual-agonist and tri-agonist. Currently, the single-agonist segment holds the maximum share of the GLP-1 market. It is worth highlighting that tri-agonist segment is likely to grow at a relatively higher CAGR.

Oral Route of Administration is the Fastest Growing Segment in the GLP-1 Market During the Forecast Period

Based on the route of administration, the market is segmented into oral route and parenteral route. At present, the parenteral route holds a larger share of the GLP-1 market. This trend is likely to remain the same in the coming decade. Further, it is worth noting that oral route of administration is likely to grow at a relatively higher CAGR.

Type 2 Diabetes Accounts for the Largest Share of the GLP-1 Market

Based on the target indication, the market is segmented into Alzheimer's Disease, non-alcoholic steatohepatitis, obesity, sleep apnea, and type 2 diabetes. While type 2 diabetes account for a relatively higher market share, it is worth highlighting that the non-alcoholic steatohepatitis segment is expected to witness substantial market growth in the coming years.

North America Accounts for the Largest Share of the Market

Based on key geographical regions, the market is segmented into North America, Europe, Asia-Pacific and Latin America. It is worth highlighting that, over the years, the market in Asia-Pacific is expected to grow at a higher CAGR.

Example Players in the GLP-1 Market

• AstraZeneca
• Biolingus
• Boehringer Ingelheim
• D&D Pharmatech
• Eli Lilly
• Gmax Biopharm
• Hanmi Pharmaceutical
• Innogen
• Novo Nordisk
• PegBio
• Pfizer
• QL Biopharma
• Roche
• Sanofi
• Sciwind Biosciences
• Tonghua Dongbao Pharmaceutical
• Viking Therapeutics
• Vivani
• vTv Therapeutic

GLP-1 MARKET: RESEARCH COVERAGE

• Market Sizing and Opportunity Analysis: The report features an in-depth analysis of the GLP-1 market, focusing on key market segments, including [A] type of molecule, [B] active compound used, [C] type of glp-1 agonist drugs, [D] type of agonist, [E] target indication and [F] geographical regions.
• Market Landscape: A comprehensive evaluation of GLP-1 drugs, considering various parameters, such as [A] stage of development, [B] type of molecule, [C] active compound used, [D] GLP-1 agonist, [E] route of administration, [F] dosing frequency, [G] type of therapy, [H] target indication and [I] therapeutic area. Additionally, it provides a detailed list of developers engaged in developing GLP-1 drugs, along with information on various parameters, such as [J] year of establishment, [K] company size (in terms of employee count) and [L] location of headquarters.
• Company Profiles: In-depth profiles of key industry players engaged in the development of GLP-1 drugs, focusing on [A] company overviews, [B] financial information, [C] drug portfolio, [D] recent developments and [E] an informed future outlook.
• Partnerships and Collaborations: An analysis of partnerships established in this sector, since 2020, based on several parameters, such as [A] year of partnership, [B] type of partnership, [C] type of molecule, [D] type of partner, [E] most active players (in terms of the number of partnerships signed) and [F] regional distribution of partnership activity in this domain.
• Market Impact Analysis: The report analyzes various factors such as drivers, restraints, opportunities, and challenges affecting the market growth.

KEY QUESTIONS ANSWERED IN THIS REPORT

• How many companies are currently engaged in this market?
• Which are the leading companies in this market?
• What kind of partnership models are commonly adopted by industry stakeholders?
• What factors are likely to influence the evolution of this market?
• What is the current and future market size?
• What is the CAGR of this market?
• How is the current and future market opportunity likely to be distributed across key market segments?

REASONS TO BUY THIS REPORT

• The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
• Stakeholders can leverage the report to gain a deeper understanding of the competitive dynamics within the market. By analyzing the competitive landscape, businesses can make informed decisions to optimize their market positioning and develop effective go-to-market strategies.
• The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.

ADDITIONAL BENEFITS

• Complimentary PPT Insights Packs
• Complimentary Excel Data Packs for all Analytical Modules in the Report
• 10% Free Content Customization
• Detailed Report Walkthrough Session with Research Team
• Free Updated report if the report is 6-12 months old or older

TABLE OF CONTENTS

1. BACKGROUND

• 1.1. Context
• 1.2. Project Objectives

2. RESEARCH METHODOLOGY

• 2.1. Chapter Overview
• 2.2. Research Assumptions
• 2.3. Project Methodology
• 2.4. Forecast Methodology
• 2.5. Robust Quality Control
• 2.6. Key Market Segmentations
• 2.7. Key Considerations
  • 2.7.1. Demographics
  • 2.7.2. Economic Factors
  • 2.7.3. Government Regulations
  • 2.7.4. Supply Chain
  • 2.7.5. COVID Impact
  • 2.7.6. Market Access
  • 2.7.7. Healthcare Policies
  • 2.7.8. Industry Consolidation

3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS

• 3.1. Chapter Overview
• 3.2. Market Dynamics
  • 3.2.1. Time Period
    • 3.2.1.1. Historical Trends
    • 3.2.1.2. Current and Forecasted Estimates
  • 3.2.2. Currency Coverage and Foreign Exchange Rate
    • 3.2.2.1. Major Currencies Affecting the Market
    • 3.2.2.2. Factors affecting Currency Fluctuations and Foreign Exchange Rates
    • 3.2.2.3. Impact of Foreign Exchange Rate Volatility on Market
    • 3.2.2.4. Strategies For Mitigating Foreign Exchange Risk
  • 3.2.3. Trade Policies
    • 3.2.3.1. Impact of Trade Barriers on the Market
    • 3.2.3.2. Strategies for Mitigating the Risks Associated with Trade Barriers
  • 3.2.4. Recession
    • 3.2.4.1. Historical Analysis of Past Recessions and Lessons Learnt
    • 3.2.4.2. Assessment of Current Economic Conditions and Potential Impact on the Market
  • 3.2.5. Inflation
    • 3.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
    • 3.2.5.2. Potential Impact of Inflation on the Market Evolution

4. EXECUTIVE SUMMARY

5. INTRODUCTION

• 5.1. Overview of the GLP-1 Drug
  • 5.1.1. Challenges Associated with GLP-1 Drugs
  • 5.1.2. Mechanism of Action of GLP-1 Drugs
• 5.2. Important Facts in GLP-1 Domain
• 5.3. Future Perspectives

6. MARKET LANDSCAPE: GLP-1 DRUGS

• 6.1. GLP-1 Drugs: Market Landscape
  • 6.1.1. Analysis by Status of Development
  • 6.1.2. Analysis by Type of Molecule
  • 6.1.3. Analysis by Active Compound Used
  • 6.1.4. Analysis by Type of Agonist
  • 6.1.5. Analysis by Route of Administration
  • 6.1.6. Analysis by Dosing Frequency
  • 6.1.7. Analysis by Type of Therapy
  • 6.1.8. Analysis by Target Indication
  • 6.1.9. Analysis by Therapeutic Area
• 6.2. GLP-1 Drugs: Developer Landscape
  • 6.2.1. Analysis by Year of Establishment
  • 6.2.2. Analysis by Company Size
  • 6.2.3. Analysis by Location of Headquarters
  • 6.2.3. Analysis by Location of Headquarters (Country) and Status of Development
  • 6.2.4. Most Active Developers: Analysis by Number of Therapies

7. GLP-1 DRUGS: DETAILED COMPANY PROFILES

• 7.1. Chapter Overview
  • 7.2.1. AstraZeneca
    • 7.1.1.1. Company Overview
    • 7.1.1.2. Pipeline Portfolio
    • 7.1.1.3. Financial Details
    • 7.1.1.4. Recent Developments and Future Outlook
  • 7.1.2. D&D Pharmatech
    • 7.1.2.1. Company Overview
    • 7.1.2.2. Pipeline Portfolio
    • 7.1.2.3. Financial Details
    • 7.1.2.4. Recent Developments and Future Outlook
  • 7.1.3. Eli Lilly
    • 7.1.3.1. Company Overview
    • 7.1.3.2. Pipeline Portfolio
    • 7.1.3.3. Financial Details
    • 7.1.3.4. Recent Developments and Future Outlook
  • 7.1.4. Novo Nordisk
    • 7.1.4.1. Company Overview
    • 7.1.4.2. Pipeline Portfolio
    • 7.1.4.3. Financial Details
    • 7.1.4.4. Recent Developments and Future Outlook
  • 7.1.5. Pfizer
    • 7.1.5.1. Company Overview
    • 7.1.5.2. Pipeline Portfolio
    • 7.1.5.3. Financial Details
    • 7.1.5.4. Recent Developments and Future Outlook
  • 7.1.6. Sanofi
    • 7.1.6.1. Company Overview
    • 7.1.6.2. Pipeline Portfolio
    • 7.1.6.3. Financial Details
    • 7.1.6.4. Recent Developments and Future Outlook
  • 7.1.7. Tonghua Dongbao Pharmaceutical
    • 7.1.7.1. Company Overview
    • 7.1.7.2. Pipeline Portfolio
    • 7.1.7.3. Financial Details
    • 7.1.7.4. Recent Developments and Future Outlook
  • 7.1.8. Vivani
    • 7.1.8.1. Company Overview
    • 7.1.8.2. Pipeline Portfolio
    • 7.1.8.3. Financial Details
    • 7.2.8.4. Recent Developments and Future Outlook

8. GLP-1 DRUGS: BRIEF COMPANY PROFILES

• 8.1. Chapter Overview
  • 8.1.1. Biolingus
    • 8.1.1.1. Company Overview
    • 8.1.1.2. Pipeline Portfolio
  • 8.1.2. Boehringer Ingelheim
    • 8.1.2.1. Company Overview
    • 8.1.2.2. Pipeline Portfolio
  • 8.1.3. Gmax Biopharm
    • 8.1.3.1. Company Overview
    • 8.1.3.2. Pipeline Portfolio
  • 8.1.4. Hanmi Pharmaceutical
    • 8.1.4.1. Company Overview
    • 8.1.4.2. Pipeline Portfolio
  • 8.1.5. Innogen
    • 8.1.5.1. Company Overview
    • 8.1.5.2. Pipeline Portfolio
  • 8.1.6. PegBio
    • 8.1.6.1. Company Overview
    • 8.1.6.2. Pipeline Portfolio
  • 8.1.7. QL Biopharma
    • 8.1.7.1. Company Overview
    • 8.1.7.2. Pipeline Portfolio
  • 8.1.8. Roche
    • 8.1.8.1. Company Overview
    • 8.1.8.2. Pipeline Portfolio
  • 8.1.9. Sciwind Biosciences
    • 8.1.9.1. Company Overview
    • 8.1.9.2. Pipeline Portfolio
  • 8.1.10. Viking Therapeutics
    • 8.1.10.1. Company Overview
    • 8.1.10.2. Pipeline Portfolio
  • 8.1.11. vTv Therapeutics
    • 8.1.11.1. Company Overview
    • 8.1.11.2. Pipeline Portfolio

9. PARTNERSHIPS AND COLLABORATIONS

• 9.1. Chapter Overview
• 9.2. Partnership Models
• 9.3. GLP-1 Market: Partnerships and Collaborations
  • 9.3.1. Analysis by Year of Partnership
  • 9.3.2. Analysis by Type of Partnership
  • 9.3.3. Analysis by Focus Area
  • 9.3.4. Analysis by Year and Type of Partnership
  • 9.3.5. Most Active Players: Analysis by Number of Partnerships
  • 9.3.7. Analysis by Geography
    • 9.3.7.1. Intercontinental and Intracontinental Deals
    • 9.3.7.2. Local and International Deals

10. MARKET IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES

• 10.1. Chapter Overview
• 10.2. Market Drivers
• 10.3. Market Restraints
• 10.4. Market Opportunities
• 10.5. Market Challenges
• 10.6. Conclusion

11. GLOBAL GLP-1 MARKET

• 11.1. Assumptions and Methodology
• 11.2. Global GLP-1 Market, Historical Trends and Forecasted Estimates, till 2035
  • 11.2.1. Scenario Analysis
    • 11.2.1.1. Conservative Scenario
    • 11.2.1.2. Optimistic Scenario
  • 11.2.2. Key Market Segmentations

12. GLP-1 MARKET, BY TYPE OF MOLECULE

• 12.1. Assumptions and Methodology
• 12.2. GLP-1 Market: Distribution by Type of Molecule, 2020, 2024 and 2035
  • 12.2.1. GLP-1 Market for Biologics, till 2035
  • 12.2.2. GLP-1 Market for Small Molecules, till 2035
• 12.3. Data Triangulation and Validation

13. GLP-1 MARKET, BY ACTIVE COMPOUND USED

• 13.1. Assumptions and Methodology
• 13.2. GLP-1 Market: Distribution by Active Compound Used, 2020, 2024 and 2035
  • 13.2.1. GLP-1 Market for Dulaglutide, till 2035
  • 13.2.2. GLP-1 Market for liraglutide, till 2035
  • 13.2.3. GLP-1 Market for Orforglipron, till 2035
  • 13.2.4. GLP-1 Market for Retatrutide, till 2035
  • 13.2.5. GLP-1 Market for Semaglutide, till 2035
  • 13.2.6. GLP-1 Market for Survodutide, till 2035
  • 13.2.7. GLP-1 Market for Tirzepatide, till 2035
  • 13.2.8. GLP-1 Market for Other Active Compounds, till 2035
• 13.3 Data Triangulation and Validation

14. GLP-1 MARKET, BY TYPE OF GLP-1 AGONIST DRUGS

• 14.1. Assumptions and Methodology
• 14.2. GLP-1 Market: Distribution by Type Of GLP-1 Agonist Drugs, 2020, 2024 and 2035
  • 14.2.1. GLP-1 Market for Long-acting GLP-1 Agonist, till 2035
  • 14.2.2. GLP-1 Market for Short-acting GLP-1 Agonist, till 2035
• 14.3. Data Triangulation and Validation

15. GLP-1 MARKET, BY GLP-1 AGONIST

• 15.1. Assumptions and Methodology
• 15.2. GLP-1 Market: Distribution by GLP-1 Agonist, 2020, 2024 and 2035
  • 15.2.1. GLP-1 Market for Single-agonist, till 2035
  • 15.2.2. GLP-1 Market for Dual-agonist, till 2035
  • 15.2.3. GLP-1 Market for Tri-agonist, till 2035
• 15.3. Data Triangulation and Validation

16. GLP-1 MARKET, BY ROUTE OF ADMINISTRATION

• 16.1. Assumptions and Methodology
• 16.2. GLP-1 Market: Distribution by Route of Administration, 2020, 2024 and 2035
  • 16.2.1. GLP-1 Market for Oral Route, till 2035
  • 16.2.2. GLP-1 Market for Parenteral Route, till 2035
• 16.3. Data Triangulation and Validation

17. GLP-1 MARKET, BY TARGET INDICATION

• 17.1. Assumptions and Methodology
• 17.2. GLP-1 Market: Distribution by Target Indication, 2020, 2024 and 2035
  • 17.2.1. GLP-1 Market for Alzheimer's Disease, till 2035
  • 17.2.2. GLP-1 Market for Non-Alcoholic Steatohepatitis, till 2035
  • 17.2.3. GLP-1 Market for Obesity, till 2035
  • 17.2.4. GLP-1 Market for Sleep Apnea, till 2035
  • 17.2.5. GLP-1 Market for Type 2 Diabetes, till 2035
• 17.3. Data Triangulation and Validation

18. GLP-1 MARKET, BY GEOGRAPHY

• 18.1. Assumptions and Methodology
• 18.2. GLP-1 Market: Distribution by Geography, 2020, 2024 and 2035
  • 18.2.1. GLP-1 Market in North America, till 2035
  • 18.2.2. GLP-1 Market in Europe, till 2035
  • 18.2.3. GLP-1 Market in Asia-Pacific, till 2035
  • 18.2.4. GLP-1 Market in Latin America, till 2035
• 18.3. Data Triangulation and Validation

19. GLP-1 MARKET, SALES FORECAST OF GLP-1 DRUGS

• 19.1. Chapter Overview
• 19.2. Approved GLP-1 Drugs: Sales Forecast
  • 19.2.1. Feisumei (Benaglutide) Sales Forecast
  • 19.2.2. Fu Laimei (Polyethylene Glycol Loxenatide) Sales Forecast
  • 19.2.3. Mounjaro (Tirzepatide) Sales Forecast
  • 19.2.4. Ozempic (Semaglutide Subcutaneous) Sales Forecast
  • 19.2.5. Rybelsus (Semaglutide Oral) Sales Forecast
  • 19.2.6. Saxenda (Liraglutide) Sales Forecast
  • 19.2.7. Trulicity (Dulaglutide) Sales Forecast
  • 19.2.8. Victoza (Liraglutide) Sales Forecast
  • 19.2.9. Wegovy (Semaglutide Subcutaneous) Sales Forecast
  • 19.2.10. XULTOPHY (Insulin Degludec / Liraglutide) Sales Forecast
  • 19.2.11. Zepbound (Tirzepatide) Sales Forecast
• 19.3. Phase III GLP-1 Drugs: Sales Forecast
  • 19.3.1. GMA102 / Glutazumab Sales Forecast
  • 19.3.2. JY09 Sales Forecast
  • 19.3.3. LY3298176 / Tirzepatide Sales Forecast
  • 19.3.4. Mazdutide / LY3305677/ IBI-362 Sales Forecast
  • 19.3.5. Orforglipron / LY3502970 Sales Forecast
  • 19.3.6. PB-119 / PEG-exenatide / Polyethylene glycol exenatide Sales Forecast
  • 19.3.7. Retatrutide / LY3437943 Sales Forecast
  • 19.3.8. Semaglutide Oral Sales Forecast
  • 19.3.9. Semaglutide Subcutaneous Sales Forecast
  • 19.3.10. Survodutide / BI 456906 Sales Forecast
  • 19.3.11. XW003 / Ecnoglutide Sales Forecast
  • 19.3.12. YN011-isupaglutide Sales Forecast

20. GLP-1 MARKET, BY LEADING DRUG DEVELOPERS

• 20.1. Chapter Overview
• 20.2. GLP-1 Market: Distribution by Leading Drug Developers, 2020 (USD Million)
• 20.3. GLP-1 Market: Distribution by Leading Drug Developers, 2024 (USD Million)
• 20.4. GLP-1 Market: Distribution by Leading Drug Developers, 2035 (USD Million)

21. APPENDIX 1: TABULATED DATA

22. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

관련자료